Minoxidil alone is often insufficient for treating hair loss because it doesn't address the DHT-related cause. Combining it with finasteride, a DHT blocker, is generally more effective.
The conversation discusses the confusion over low testosterone potentially causing hair loss, with users sharing personal experiences and knowledge about hair loss treatments like Finasteride. Some users suggest that hairfollicle sensitivity to DHT, not testosterone levels, is the key factor in balding, and others discuss the side effects of hair loss medications.
Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.
Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-relatedhair loss treatments.
The conversation discusses why DHT (dihydrotestosterone) negatively affects scalp hair but promotes growth elsewhere on the body. Various opinions include genetic predispositions, differences in hairfollicle reactions to DHT, and the potential role of Omega-3 in reducing inflammation and promoting hair health.
Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.
Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.
PP405 is a new hair loss treatment targeting dormant hairfollicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
PP405 shows promise for hairfollicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
A potential treatment for alopecia involving a protein that calms hairfollicles has shown promise in rats, but skepticism remains about its applicability to humans. Many users express doubt about the timeline for effective hair loss treatments, comparing it to past unfulfilled promises.
PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.
Scalp Botox may help hair loss by relaxing muscles and increasing blood flow, potentially benefiting conditions other than androgenetic alopecia. DHT affects hairfollicles differently, causing tension and hair loss in some areas but not others.
Hair loss treatment should target dermal white adipose tissue (DWAT) to restore hairfollicles. Potential remedies include tocopherol (vitamin E), botox, rosiglitazone, niacin, kojyl cinnamate esters, and ADP355.
Hair loss treatments still rely heavily on minoxidil, finasteride, and RU58841, with little innovation. Future treatments like stem cell therapy and RNA technology show promise but are not yet available.
Deoxyribose sugar gel may stimulate hair regrowth similarly to minoxidil by enhancing blood supply and follicle activity. Human trials are necessary, and current products have mixed results.
Hair loss treatments include finasteride, minoxidil, microneedling, dutasteride, CB-03-01, RU-58841, and experimental options like KY-19382 and stem cell therapy. Some treatments are considered ineffective or risky, such as ketoconazole, PRP, and low-level laser therapy.
The conversation is about a meme related to hair loss that influenced someone to start taking finasteride. Another person agrees that the meme accurately represents the situation.
PP405 is a promising new hair loss treatment that may reactivate dormant hairfollicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.
TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hairfollicle sensitivity to DHT.
PP405 is not a cure for hair loss but may reactivate dormant hairfollicles, similar to minoxidil. It is unlikely to help with miniaturized or vellus hairs and is still in trial phases, with availability expected around 2030.
A potential treatment for hair loss that involves injecting fat into the scalp; the role of testosterone and estrogen in thinning fat tissue under the skin; research on using lard to treat androgenic alopecia, as well as PRP + ACELL/amniotic stem cell treatments; and ongoing clinical trials by doctors involved in the study.
Minoxidil and finasteride are discussed for hair loss, with concerns about minoxidil's heart-related side effects. New treatments like PP405 are met with skepticism, often humorously noted as always being "five years away."
High DHEA levels may contribute to hair loss by increasing DHT in hairfollicles, potentially explaining why finasteride is ineffective for some. Treatments like high-dose dutasteride and RU58841 are suggested, but the underlying cause, such as adrenal issues, should be investigated.
Users discuss potential game-changing hair loss treatments in the next 10 years. Some mention KX-826, SCUBE3, and stem cells as promising options, while others express doubt due to past disappointments and lack of focused research.
The post discusses the theory that persistent dandruff in areas prone to hair loss could be a sign of hairfollicles dying due to DHT, indicating balding. The responses vary, with some users noting improvements in dandruff and hair loss with treatments like Dutasteride, while others experienced hair loss without dandruff.
The conversation discusses making a topical melatonin solution for hair loss treatment, questioning if isopropyl alcohol can dissolve melatonin. Melatonin is soluble in lipids and alcohol, but it's unstable and should be mixed fresh regularly; it may help hair growth by affecting certain cellular signaling pathways and has anti-androgenic effects.
Minoxidil's effectiveness is limited by the need for sulfation and proper transport to hairfollicles, with tretinoin potentially enhancing its effects by promoting enzyme activity and keratinocyte differentiation. Tretinoin may improve minoxidil's response by boosting the expression of necessary enzymes and transporters.
Dutasteride is more effective than finasteride for hair loss as it blocks more of the enzyme causing hair loss. New treatments like stem cell therapies and alternatives to minoxidil are being explored, but major advancements are still years away.
Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hairfollicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.
ET-02, a PAI-1 inhibitor, is not proven to be more effective than Minoxidil for hair loss. Other treatments like finasteride, dutasteride, PP405, and AMP-303 are also discussed, focusing on cellular senescence and oxidative stress.